Top Markets
#1 bitcastle Token bitcastle Token +150.75%
#2 MowCat MowCat +86.64%
#3 MarsCoin MarsCoin +56.26%
#4 Palladium Network Palladium Network +53.30%
#5 Siren Siren +29.58%
#6 Bedrock Bedrock +25.17%
#7 Useless Coin Useless Coin +24.14%
#8 Pons Pons +19.31%
#9 ICON ICON +18.24%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.16%
Coin of the day
bitcastle Token bitcastle Token
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Innate Pharma S.A. Innate Pharma S.A.

Innate Pharma S.A.

IPH
Classifica tra le azioni #18357
Innate Pharma S.A. is a biotechnology firm dedicated to the discovery,... Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company's pipeline includes several key drug candidates: Lacutamab (IPH4102), an anti-KIR3DL2 antibody, is currently in Phase II clinical trials for treating cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab, an immune checkpoint inhibitor, is undergoing Phase III evaluation for advanced solid tumors, encompassing colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401), a monoclonal antibody designed to block C5a binding to C5aR1, is advancing through Phase II studies for conditions such as COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases. IPH5201, a blocking antibody, is in Phase I clinical trials, aiming to modulate the CD39 immunosuppressive pathway. IPH5301, an anti-CD73 antibody, targets the immunosuppressive adenosine pathway to foster anti-tumor immunity. IPH6101, an NKp46-based NK cell engager, is being developed for the creation and assessment of up to two bispecific NK cell engagers. Beyond clinical stages, their preclinical programs feature IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), along with the IPH62 and IPH64 programs. Innate Pharma S.A. maintains strategic alliances and licensing deals with prominent pharmaceutical entities including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, in addition to a co-development and licensing agreement with MedImmune Limited. The company was founded in 1999 and has its headquarters located in Marseille, France.
Prezzo delle azioni
$2.15
Capitalizzazione di mercato
$201.60M
Variazione (1 giorno)
0.56%
Variazione (1 anno)
-1.01%
Paese
FR
Scambia Innate Pharma S.A. (IPH)

Categoria

Healthcare
Storico del rendimento da dividendi per Innate Pharma S.A. (IPH)
Il rendimento da dividendi (TTM) di Innate Pharma S.A. (simbolo azionario: IPH) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Innate Pharma S.A. (IPH) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.48%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH